Breast cancer risk associated with estrogen exposure and truncating mutation location in BRCA1/2 carriers

Julie Lecarpentier, Catherine Noguès, Emmanuelle Mouret-Fourme, Bruno Buecher, Marion Gauthier-Villars, Dominique Stoppa-Lyonnet, Valèrie Bonadona, Jean Pierre Fricker, Pascaline Berthet, Olivier Caron, Isabelle Coupier, Pascal Pujol, Laurence Faivre, Paul Gesta, François Eisinger, Véronique Mari, Laurence Gladieff, Alain Lortholary, Elisabeth Luporsi, Dominique LerouxLaurence Venat-Bouvet, Christine M. Maugard, Chrystelle Colas, Julie Tinat, Christine Lasset, Nadine Andrieu

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    18 Citations (Scopus)

    Résumé

    Background: Mutations in BRCA1/2 confer a high risk of breast cancer, but literature values of this risk vary. A genotype-phenotype correlation has been found in both genes, and the effect of reproductive factors differs according to mutation location. Therefore, we hypothesize that such a variation may exist for other factors related to estrogen exposure. Methods: We used a weighted Cox regression model to assess variation in breast cancer risk with these factors using location of mutation in homogeneous breast cancer risk region of BRCA1/2 in the GENEPSO study. Results: We found that late age at menarche reduced breast cancer risk by 31%and thatamong BRCA1 carriers, a long or a short menstrual cycle increased risk (by 65% and 73%, respectively). Among premenopausal women, overweight was associated with a 45% decrease in risk whereas underweight was associated with an increased risk (HR, 2.40). A natural menopause, mainly after age 50, was associated with a high breast cancer risk (HR, 2.46), and a significant interaction between menopause status and the location of mutations was found leading up to 10% variation in absolute risk according to the age at menopause. Conclusions: As observed in the general population, a late menarche, a long or a short menstrual cycle, over-or underweight, and being postmenopausal were associated with breast cancer risk in BRCA1/2 carriers. The association with the menopause was observed only when the mutation was located in the "high-risk" zones. Impact: Taking into account modifier factors, location of mutation might be important for the clinical management of BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev; 24(4); 698-707.

    langue originaleAnglais
    Pages (de - à)698-707
    Nombre de pages10
    journalCancer Epidemiology Biomarkers and Prevention
    Volume24
    Numéro de publication4
    Les DOIs
    étatPublié - 1 avr. 2015

    Contient cette citation